<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504372</url>
  </required_header>
  <id_info>
    <org_study_id>3475-091</org_study_id>
    <secondary_id>2015-000575-27</secondary_id>
    <secondary_id>EORTC-1416-LCG</secondary_id>
    <secondary_id>163457</secondary_id>
    <nct_id>NCT02504372</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)</brief_title>
  <acronym>PEARLS</acronym>
  <official_title>A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ETOP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have
      undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant
      chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is
      that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2015</start_date>
  <completion_date type="Anticipated">August 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Up to 100 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 100 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Cancer Specific Survival (LCSS)</measure>
    <time_frame>Up to 100 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1380</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathological diagnosis of NSCLC confirmed at surgery, any histology

          -  Union for International Cancer Control (UICC) v7 Stage IB with T ≥ 4 cm, II-IIIA NSCLC
             after complete surgical resection with resection margins proved microscopically free
             of disease (R0). Carcinoma in situ can be present at the bronchial margin

          -  Available tumor sample obtained at surgical resection for programmed cell death
             ligand-1 (PD-L1) Immunohistochemistry (IHC) expression assessment

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

          -  Adequate organ function performed within 10 days of treatment initiation

          -  Female participants of childbearing potential must have a negative urine or serum
             pregnancy test at screening (within 72 hours of first dose of study medication). If
             the urine test cannot be confirmed as negative, a serum pregnancy test will be
             required. The serum pregnancy test must be negative for the participant to be eligible

          -  Female participants of childbearing potential should be willing to use 2 methods of
             birth control or be surgically sterile, or abstain from heterosexual activity for the
             course of the study through 120 days after the last dose of study treatment

          -  Female participants who are breast feeding should discontinue nursing prior to the
             first dose of study medication and until 120 days after the last study treatment

          -  Male participants should agree to use an adequate method of contraception starting
             with the first dose of study treatment through 120 days after the last dose of study
             treatment

          -  Absence of severe comorbidities that in the opinion of the Investigator might hamper
             the participation to the study and/or the treatment administration

          -  No prior or foreseen neo-adjuvant or adjuvant radiotherapy and/or neo-adjuvant
             chemotherapy

        Exclusion Criteria:

          -  Evidence of disease at clinical examination and/or baseline radiological assessment as
             documented by contrast enhanced chest/upper abdomen CT scan, brain CT/MRI and clinical
             examination

          -  More than 4 cycles of adjuvant therapy

          -  Prior treatment with anti-programmed cell death (anti-PD)-1, anti-PD ligand-1/2,
             anti-CD137, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulators

          -  Live vaccine within 30 days prior to the first dose of study treatment

          -  Current participation or treatment with an investigational agent or use of an
             investigational device within 4 weeks of the first dose of study treatment

          -  History of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies positive). No
             known active Hepatitis B or C

          -  Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in
             the last 3 days prior to the first dose of study treatment

          -  History of interstitial lung disease or (non-infectious) pneumonitis that required
             oral or IV steroids (other than COPD exacerbation) or current pneumonitis

          -  Active autoimmune disease that has required systemic treatment in past 2 years

          -  History of a hematologic or primary solid tumor malignancy, unless in remission for at
             least 5 years with the exception of pT1-2 prostatic cancer Gleason score &lt; 6,
             superficial bladder cancer, non melanomatous skin cancer or carcinoma in situ of the
             cervix

          -  Previous allogeneic tissue/solid organ transplant

          -  Active infection requiring therapy

          -  Surgery- or chemotherapy-related toxicity not resolved to Grade 1 with the exception
             of alopecia, fatigue, neuropathy and lack of appetite /nausea

          -  Pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of study treatment

          -  Participant will not be eligible if the participant is or has an immediate family
             member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational
             site or Sponsor staff directly involved with this trial, unless prospective site
             Review Board approval is given allowing exception to this criterion for a specific
             participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>North Ryde</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Australian Medical Information Centre</last_name>
      <phone>61 2 8988 8428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Osterreich GmbH</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaudia Georgi</last_name>
      <phone>41586183388</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Belgium BVBA/SPRL</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Antonissen</last_name>
      <phone>32 27766501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Brasil</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MSD Online</last_name>
      <phone>0800 012 22 32</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Canada</name>
      <address>
        <city>Kirkland</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Information Centre Centre d'information medicale Merck Canada Inc.</last_name>
      <phone>514-428-8600 / 1-800-567-2594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (I.A.) Corp.</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Morales</last_name>
      <phone>56-2-26558912</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD SRO Czechýýýýýýýýýýýýýýý</name>
      <address>
        <city>Prague</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas J. Johansson</last_name>
      <phone>420 233 010 111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>46857813545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme OU</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>460857813500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Bouchara</last_name>
      <phone>33 180464417</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vianex, S.A. / MSD</name>
      <address>
        <city>Alimos</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Aletra</last_name>
      <phone>30 2109897318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Pharma Hungary Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szabolcs Barotfi</last_name>
      <phone>36 1 888 5300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Ireland (Human Health) Ltd.</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Duffy</last_name>
      <phone>44 01992455265</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Co. Ltd.</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Goldstaub</last_name>
      <phone>972-9-9533326</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Italia S.r.l.</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Chiaretta Fattore</last_name>
      <phone>39 0636191739</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD K.K.</name>
      <address>
        <city>Chiyoda-Ku, Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Japan Call Center</last_name>
      <phone>81-3-6272-1957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Korea LTD</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TaeYoun Jo</last_name>
      <phone>8223312313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Latvija SIA</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>460857813500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme BV</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arjan Ooms</last_name>
      <phone>31235153306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme, Peru S.R.L.</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolfo Lozano</last_name>
      <phone>5114115910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Polska Sp. Z o.o.</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas J. Johansson</last_name>
      <phone>48224784324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Lda.</name>
      <address>
        <city>Paco D'arcos</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Lopez-Bravo</last_name>
      <phone>(0034) 913210654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme IDEA, Inc.</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Serebriakova</last_name>
      <phone>74959167100, EXT.366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Inovativna zdravilla</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szabolcs Barotfi</last_name>
      <phone>36 1 888 5300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Lopez-Bravo</last_name>
      <phone>(0034) 913210654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD International GmbH</name>
      <address>
        <city>Lucerne 6</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaudia Georgi</last_name>
      <phone>41586183388</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ilaclari Ltd. Sti</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betul Erdogan</last_name>
      <phone>2123361232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ltd.</name>
      <address>
        <city>Hoddesdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Duffy</last_name>
      <phone>44 01992455265</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>PDL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

